The short-term efficacy and tolerability of @entity3756 for adults with @entity245 ( @entity245 ) were assessed in this investigation. Forty-two adults with @entity245 ( @entity2438 , N = 22; @entity13104 , N = 6; and @entity3602 not otherwise specified [NOS], N = 14) participated in a 12-week, open-label, systematic trial of @entity3756 . Behavioral ratings of repetitive symptoms, @entity146 , and social relatedness were obtained at baseline and after 4, 8, and 12 weeks of @entity3756 administration. Twenty-four (57%) of 42 @entity1 showed significant improvement, primarily in repetitive and aggressive symptoms. Statistically significant changes in measures of social relatedness did not occur. @entity1 with @entity2438 and @entity3602 NOS did significantly better than those with @entity13104 . Based on global improvement item criteria from the Clinical Global Impression Scale, 15 of 22 (68%) @entity1 with @entity2438 , none of six (0%) @entity1 with @entity13104 , and 9 of 14 (64%) @entity1 with @entity3602 NOS were categorized as treatment responders. @entity3756 was well tolerated; no adverse cardiovascular effects, @entity21 , or @entity410 were identified. These findings suggested that @entity3756 may be an effective treatment for interfering repetitive and aggressive symptoms in adults with @entity245 . Definitive statements about the efficacy and tolerability of @entity3756 for treating adults with @entity245 must await results from double-blind, placebo-controlled trials. These preliminary results should not be generalized to include @entity1 and adolescents with @entity245 .

XXXX in adults with @entity245 : a prospective open-label investigation.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'children'] @entity3602 :: ('MESH:D003966', 'Disease') :: ['PDD'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggression'] @entity245 :: ('MESH:D002658', 'Disease') :: ['pervasive developmental disorders', 'PDDs'] @entity2438 :: ('MESH:D001321', 'Disease') :: ['autistic disorder'] @entity13104 :: ('MESH:D020817', 'Disease') :: ["Asperger's disorder"] @entity3756 :: ('MESH:D020280', 'Chemical') :: ['Sertraline', 'sertraline'] @entity21 :: ('MESH:D001480', 'Disease') :: ['extrapyramidal symptoms']
@entity3756 :: (MESH:D020280,Chemical) :: ['Sertraline']
